Around half (50.2%) of patients with B-cell lymphoma are diagnosed with diffuse large B cell lymphoma (DLBCL) ( 1). Accepted for publication Jul 23, 2020.ī-cell lymphoma is a heterogeneous disease which comprises up to 66.3% of all lymphoma cases in China. Keywords: Trial registration: This trial is registered at (NCT01865617). Among the small sample size in this study, it demonstrated high efficiency and safety. Interleukin-1β (IL-1β), interferon-γ (IFN-γ), interleukin-10 (IL-10), and interleukin-17A (IL-17A) appeared to be associated with the occurrence of CRS and CRES.Ĭonclusions: Anti-CD19 CAR T-cell treatment is a new therapy for patients with relapsed and refractory B-cell lymphoma. The immunoglobulin levels of the four patients who died showed a significant downward trend. The occurrence of adverse reactions was not significantly related to the infusion dose, peak amplification time, or maximum copy amount. The incidence of Grade 2 cytokine release syndrome (CRS) was 36.4% (4/11), and Grade 3 CAR T-cell-related encephalopathy syndrome (CRES) was experienced by 1 patient. Each of the 4 patients in the study who had diffuse large B cell lymphoma (DLBCL) progression all had high myc protein expression (positive incidence: 30–80%). The patients who received 3 or 4 lines of chemotherapy were more likely to have sustained remission than the patients who received 4 lines of chemotherapy. As of December 7, 2019, 5 patients had maintained CR for a period exceeding 1 year, including 2 patients who had maintained CR for more than 1,000 days. After 3 months of treatment, the complete remission (CR) rate was 63.6% (7/11). The median overall survival (OS) and median progression-free survival (PFS) were not reached. The median follow-up was 253 days (range, 130–1,017 days). Results: The 11 patients in our study had a total overall response rate of 100%, after receiving anti-CD19 CAR T-cells. The number of anti-CD19 CAR T-cells, proliferation, and adverse reactions were recorded in detail, to explore the relationship between the factors affecting the efficacy of anti-CD19 CAR T-cell and the long-term survival of patients. Methods: We recruited 11 patients with relapsed and refractory B-cell lymphoma. Therefore, this study aimed to explore the factors affecting the efficacy of anti-CD19 CAR T-cell and the adverse reactions of the therapy. Policy of Dealing with Allegations of Research Misconductīackground: No effective treatment exist for patients with relapsed and refractory B-cell lymphoma, until the advent of anti-CD19 chimeric antigen receptor (CAR) T-cells.Policy of Screening for Plagiarism Process.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |